Karpe Yashashree, Chen Zhenyu, Li Xue-Jun
Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA.
Department of Bioengineering, University of Illinois at Chicago, Chicago, IL 60607, USA.
Pharmaceuticals (Basel). 2021 Jun 12;14(6):565. doi: 10.3390/ph14060565.
Motor neurons are large projection neurons classified into upper and lower motor neurons responsible for controlling the movement of muscles. Degeneration of motor neurons results in progressive muscle weakness, which underlies several debilitating neurological disorders including amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegias (HSP), and spinal muscular atrophy (SMA). With the development of induced pluripotent stem cell (iPSC) technology, human iPSCs can be derived from patients and further differentiated into motor neurons. Motor neuron disease models can also be generated by genetically modifying human pluripotent stem cells. The efficiency of gene targeting in human cells had been very low, but is greatly improved with recent gene editing technologies such as zinc-finger nucleases (ZFN), transcription activator-like effector nucleases (TALEN), and CRISPR-Cas9. The combination of human stem cell-based models and gene editing tools provides unique paradigms to dissect pathogenic mechanisms and to explore therapeutics for these devastating diseases. Owing to the critical role of several genes in the etiology of motor neuron diseases, targeted gene therapies have been developed, including antisense oligonucleotides, viral-based gene delivery, and in situ gene editing. This review summarizes recent advancements in these areas and discusses future challenges toward the development of transformative medicines for motor neuron diseases.
运动神经元是大型投射神经元,分为上运动神经元和下运动神经元,负责控制肌肉运动。运动神经元的退化会导致进行性肌肉无力,这是包括肌萎缩侧索硬化症(ALS)、遗传性痉挛性截瘫(HSP)和脊髓性肌萎缩症(SMA)在内的几种使人衰弱的神经系统疾病的基础。随着诱导多能干细胞(iPSC)技术的发展,可以从患者身上获取人iPSC,并进一步将其分化为运动神经元。通过对人类多能干细胞进行基因改造,也可以生成运动神经元疾病模型。在人类细胞中进行基因靶向的效率曾经非常低,但随着最近的基因编辑技术如锌指核酸酶(ZFN)、转录激活样效应核酸酶(TALEN)和CRISPR-Cas9的出现,效率得到了极大提高。基于人类干细胞的模型与基因编辑工具的结合为剖析致病机制和探索这些毁灭性疾病的治疗方法提供了独特的范例。由于几个基因在运动神经元疾病的病因中起着关键作用,已经开发了靶向基因疗法,包括反义寡核苷酸、基于病毒的基因递送和原位基因编辑。本综述总结了这些领域的最新进展,并讨论了开发运动神经元疾病变革性药物面临的未来挑战。